Cargando…
Engineering an Effective Human SNAP-23 Cleaving Botulinum Neurotoxin A Variant
Botulinum neurotoxin (BoNT) serotype A inhibits neurotransmitter release by cleaving SNAP-25 and represents an established pharmaceutical for treating medical conditions caused by hyperactivity of cholinergic nerves. Oversecretion from non-neuronal cells is often also the cause of diseases. Notably,...
Autores principales: | Sikorra, Stefan, Donald, Sarah, Elliott, Mark, Schwede, Susan, Coker, Shu-Fen, Kupinski, Adam P., Tripathi, Vineeta, Foster, Keith, Beard, Matthew, Binz, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766560/ https://www.ncbi.nlm.nih.gov/pubmed/33352834 http://dx.doi.org/10.3390/toxins12120804 |
Ejemplares similares
-
Botulinum neurotoxin C mutants reveal different effects of syntaxin or SNAP-25 proteolysis on neuromuscular transmission
por: Zanetti, Giulia, et al.
Publicado: (2017) -
A Highly Specific Monoclonal Antibody for Botulinum Neurotoxin Type A-Cleaved SNAP25
por: Rhéaume, Catherine, et al.
Publicado: (2015) -
Botulinum Neurotoxin F Subtypes Cleaving the VAMP-2 Q(58)–K(59) Peptide Bond Exhibit Unique Catalytic Properties and Substrate Specificities
por: Sikorra, Stefan, et al.
Publicado: (2018) -
Distribution of Cleaved SNAP-25 in the Rat Brain, following Unilateral Injection of Botulinum Neurotoxin-A into the Striatum
por: Schümann, Friederike, et al.
Publicado: (2023) -
Clostridial Neurotoxins: Mechanism of SNARE Cleavage and Outlook on Potential Substrate Specificity Reengineering
por: Binz, Thomas, et al.
Publicado: (2010)